Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 295

1.

Weight gain during treatment of bipolar I patients with olanzapine.

Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ.

J Clin Psychiatry. 2004 Dec;65(12):1679-87.

PMID:
15641874
2.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
3.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
4.

Olanzapine versus placebo in the treatment of adolescents with bipolar mania.

Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J.

Am J Psychiatry. 2007 Oct;164(10):1547-56.

PMID:
17898346
5.

Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.

Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, Ming L, Gaohua W, Xinbao Z, Huichun L, Liang S.

J Affect Disord. 2008 Jan;105(1-3):101-8. Epub 2007 May 24.

PMID:
17531327
6.

Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.

Kemp DE, Zhao J, Cazorla P, Landbloom RP, Mackle M, Snow-Adami L, Szegedi A.

J Clin Psychiatry. 2014 Mar;75(3):238-45. doi: 10.4088/JCP.12m08271.

PMID:
24499969
7.

Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.

Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O.

J Child Adolesc Psychopharmacol. 2012 Apr;22(2):157-65. doi: 10.1089/cap.2010.0020. Epub 2012 Feb 28.

PMID:
22372514
8.

Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.

Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, Chang K.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):522-30. doi: 10.1089/cap.2012.0099. Epub 2013 Oct 10.

9.
10.

The antidepressant effects of risperidone and olanzapine in bipolar disorder.

McIntyre RS, Mancini DA, Srinivasan J, McCann S, Konarski JZ, Kennedy SH.

Can J Clin Pharmacol. 2004 Fall;11(2):e218-26. Epub 2004 Oct 4.

PMID:
15520475
11.

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Citrome L, Holt RI, Walker DJ, Hoffmann VP.

Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000. Review.

PMID:
21495734
12.

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.

Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC.

BMC Psychiatry. 2013 May 14;13:138. doi: 10.1186/1471-244X-13-138.

13.

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL.

J Clin Psychiatry. 2007 Nov;68(11):1733-40.

PMID:
18052567
14.

Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.

Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, Shekhar A, Aaronson ST, Bardenstein L, Grecu-Gabos I, Tochilov V, Prelipceanu D, Oliff HS, Kryzhanovskaya L, Bowden C.

J Clin Psychiatry. 2008 Nov;69(11):1776-89. Epub 2008 Oct 7.

PMID:
19014751
15.

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.

J Clin Psychiatry. 2004;65 Suppl 18:47-56.

16.

Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.

Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF.

J Clin Psychiatry. 2001 Apr;62(4):273-81.

PMID:
11379842
17.

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.

Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL.

Am J Psychiatry. 2006 Feb;163(2):247-56.

PMID:
16449478
18.

Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

Bond DJ, Kauer-Sant'Anna M, Lam RW, Yatham LN.

J Affect Disord. 2010 Jul;124(1-2):108-17. doi: 10.1016/j.jad.2009.10.023. Epub 2009 Nov 14.

PMID:
19914720
19.

Recovery and functional outcomes following olanzapine treatment for bipolar I mania.

Chengappa KN, Hennen J, Baldessarini RJ, Kupfer DJ, Yatham LN, Gershon S, Baker RW, Tohen M.

Bipolar Disord. 2005 Feb;7(1):68-76.

PMID:
15654934
20.

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, Kodama M, Ishihara T, Kuroda S.

J Clin Psychiatry. 2008 Sep;69(9):1416-22.

PMID:
19193342

Supplemental Content

Support Center